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Abstract
High levels of the plasma peptides mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic
peptide (MR-proANP) are associated with clinical outcomes in the general population. Data in patients with chronic kidney
disease are sparse. We therefore investigated the association of MR-proANP and MR-proADM levels with all-cause and
cardiovascular (CV) mortality, CV events and peripheral arterial disease in 201 incident dialysis patients of the INVOR-Study
prospectively followed for a period of up to more than 7 years. The overall mortality rate was 43%, thereof 43% due to CV
events. Both baseline MR-proANP and MR-proADM were associated with higher risk of all-cause (HR=1.44, p=0.001 and
HR=1.32, p=0.002, respectively) and CV mortality (HR=1.75, p,0.001 and HR=1.41, p=0.007, respectively) after
adjustment for age, sex, previous CV events, diabetes mellitus and time-dependent type of renal replacement therapy. We
then stratified patients in high risk (both peptides in the upper tertile), intermediate risk (only one of the two peptides in the
upper tertile) and low risk (none in the upper tertile). Although demographic, clinical and laboratory variables were similar
among the intermediate and high risk group, to be with both parameters in the upper tertile was associated with a 3-fold
higher risk for all-cause (HR=2.87, p,0.001) and CV mortality (HR=3.58, p=0.001). In summary, among incident dialysis
patients MR-proANP and MR-proADM were shown to be associated with all-cause and CV mortality, with the highest risk
when both parameters were in the upper tertiles.
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Introduction
Patients with chronic kidney disease (CKD) are at increased risk
for death. Cardiovascular and non-cardiovascular mortality are 8
to 9 times higher in incident dialysis patients when compared to
the general population [1]. Biomarkers which predict these fatal
outcomes and provide insight into the pathogenesis are poorly
established but highly required for an early risk stratification of this
high risk cohort of patients [2,3].
There is evidence that peptides involved in maintaining the
cardiovascular and renal homeostasis such as atrial natriuretic
peptide (ANP) and adrenomedullin (ADM) may play a key role in
the compensatory mechanisms of CKD. Both hormones are
elevated in the early stages of CKD [4,5] and were shown to be
highly predictive for progression of CKD in nondiabetic patients
[6,7]. Elevated levels of ANP [8–12] and ADM [13] have been
reported to be associated with cardiac events, overall and
cardiovascular mortality in patients already on dialysis. Increased
levels of ANP and ADM have been associated with higher
mortality rates in cohorts of cardiac patients as well as in patients
with type 2 diabetes mellitus [14–17]. The two peptides might
provide additional help to estimate volume status and are
probably also an early alarm signal of deteriorating hemody-
namic changes in CKD patients. Since both peptides increase
with deteriorating kidney function [6], it is unclear whether
recently established thresholds [18] can be applied for prediction
of all-cause and cardiovascular mortality in patients with
renal disease.
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All patients
(n=201)
Survivors
(n=115)
Non-Survivors
(n=86)
Sex (male/female), n (%) 124/77 (62/38%) 69/46 (60/40%) 55/31 (64/36%)
Age (years) 61614 56615 69610
d
Diabetes mellitus, n (%) 75 (37%) 29 (25%) 46 (54%)
d
Current smokers, n (%) 44 (22%) 29 (25%) 15 (17%)
Body Mass Index (kg/m
2) 26.164.4 25.964.4 26.264.5
Start of dialysis with
Hemodialysis, n (%) 169 (84%) 93 (81%) 76 (88%)
Central venous catheter, n (%) 25 (15%) 8 (9%) 17 (22%)
a
Native fistula, n (%) 114 (67%) 73 (79%) 41 (54%)
c
Graft, n (%) 30 (18%) 12 (13%) 18 (24%)
Peritoneal dialysis, n (%) 32 (16%) 22 (19%) 10 (12%)
Year of start of dialysis
2000–2003, n (%) 98 (49%) 51 (44%) 47 (55%)
2004–2006, n (%) 103 (51%) 64 (56%) 39 (45%)
Echocardiography
Missing, n (%) 15 (7%) 5 (4%) 10 (12%)
Ejection fraction #60%, n (%) 86 (43%) 42 (37%) 44 (51%)
b
Ejection fraction .60%, n (%) 100 (50%) 68 (59%) 32 (37%)
b
Systolic blood pressure (mmHg) 153623 154622 153624
Diastolic blood pressure (mmHg) 83612 86611 79613
d
Laboratory parameters
MR-proANP (pmol/L) 7986524
[461; 669; 946]
6626439
[326; 571; 787]
9816573
d
[544; 786; 1405]
MR-proADM (nmol/L) 2.9761.29
[2.20; 2.69; 3.52]
2.7261.33
[2.05; 2.49; 3.13]
3.2961.17
d
[2.49; 3.02; 3.88]
Albumin (g/dL) 3.760.8 3.960.8 3.560.6
d
C-reactive protein (mg/dL) 3.065.4
[0.3; 0.8; 2.5]
2.664.3
[0.3; 0.7; 2.7]
3.866.5
a
[0.5; 1.0; 2.5]
Calcium (mmol/L) 2.1260.28 2.1660.27 2.0860.28
a
Phosphorus (mmol/L) 2.0060.61
[1.57; 1.94; 2.33]
1.9660.61
[1.51; 1.90; 2.25]
2.0460.61
[1.60; 2.00; 2.39]
Hemoglobin (g/dL) 11.261.7 11.561.7 10.861.6
b
Creatinine (mg/dL) 7.362.7
[5.5; 6.8; 8.7]
7.362.5
[5.5; 6.8; 8.7]
7.362.9
[5.3; 6.8; 8.4]
HbA1c (%) 6.4361.55 6.1561.32 6.7061.71
Total cholesterol (mg/dL) 189652 190649 187655
LDL cholesterol (mg/dL) 118644 121644 114642
HDL cholesterol (mg/dL) 46.4613.4 47.8613.4 44.5613.1
Triglycerides (mg/dL) 1666102
[106; 139; 192]
164686
[106; 139; 193]
1696120
[105; 137; 189]
Comorbidities before dialysis
CAD*, n (%) 36 (17.9%) 13 (11.3%) 23 (26.7%)
b
CVD**, n (%) 61 (30.3%) 23 (20.0%) 38 (44.2%)
d
PAD***, n (%) 35 (17.4%) 8 (7.0%) 27 (31.4%)
d
Follow-up
Follow-up time (months){ 55.7628.7 71.3619.2 34.8626.0
d
Transplantation, n (%) 59 (29.4%) 53 (46.1%) 6 (7.0%)
d
Mean6SD [25., 50. und 75. percentile in case of non-normal distribution] or number (%).
ap,0.05;
bp,0.01;
cp,0.005;
dp,0.001 – comparison between survivors and non-survivors.
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proANP and MR-proADM plasma concentrations at the start of
dialysis treatment are associated with risk of cardiovascular or all-
cause mortality in a prospective cohort study of incident dialysis
patients.
Methods
INVOR-Study
The INVOR-Study [19] (Study of Incident Dialysis Patients in
Vorarlberg) is a single-center, prospective, observational cohort
study of incident Caucasian hemodialysis and peritoneal dialysis
patients in Vorarlberg, the westernmost province of Austria
counting approximately 400,000 inhabitants.
Ethic statement: The study was approved by the ethics
committee of the Innsbruck Medical University and all patients
enrolled in the study provided written informed consent.
All incident dialysis patients from this province starting chronic
dialysis treatment between May 1
st, 2000 and April 30
th, 2006
were consecutively enrolled with the advantage that all patients of
this region are treated by the same care provider. During this
period of 6 years a total number of 235 incident dialysis patients
were included and followed until the study endpoint was reached
or follow-up was censored at December 31
st, 2009. Ten patients
having a malignant tumor at initiation of dialysis were not
recruited defined by the exclusion criteria. Due to inappropriate or
missing blood samples MR-proANP and MR-proADM was
measured in 201 out of 235 patients. All data and analyses
described in this manuscript are based on these 201 patients.
Data description
Clinical, laboratory and medication data were collected
prospectively starting at the time of initiation of dialysis. These
data included age, sex, height, weight, body mass index, diabetes
status and current smoking status. Type of and change in renal
replacement therapy (hemodialysis, peritoneal dialysis and kidney
transplantation) were recorded and considered as time-dependent
treatment status for data analysis. Vascular access procedures and
the type of vascular access (native fistula, graft or central venous
catheter) for hemodialysis were also evaluated.
Information on the following clinical events were collected
before initiation of dialysis and during the entire observation
period thereafter: coronary artery disease (including myocardial
infarction, percutaneous transluminal coronary angioplasty, aor-
tocoronary bypass), cardiovascular disease (including myocardial
infarction, percutaneous transluminal coronary angioplasty, aor-
tocoronary bypass, angiographically-proven coronary stenosis
$50%, sudden cardiac death, ischemic or hemorrhagic cerebral
infarction, transient ischemic attack, carotid stenosis and carotid
endarterectomy), peripheral arterial disease (significant ultra-
sound- or angiographically-proven vascular stenosis, percutaneous
transluminal angioplasty, peripheral bypass, amputation).
*Coronary artery disease (CAD): myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass.
**Cardiovascular disease (CVD): myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, angiographically-proven coronary
stenosis $50%, ischemic cerebral infarction, transient ischemic attack.
***Peripheral arterial disease (PAD): significant ultrasound- or angiographically-proven vascular stenosis, percutaneous transluminal angioplasty, peripheral bypass,
amputation.
{Follow-up time was calculated as the time from the start of dialysis until the patient died or the end of the observation period was reached.
doi:10.1371/journal.pone.0017803.t001
Table 1. Cont.
Figure 1. Kaplan-Meier survival curves with 95% confidence bands for all-cause and cardiovascular mortality. ‘‘% surv’’ stands for the
percentage of survivors at each 12-month interval.
doi:10.1371/journal.pone.0017803.g001
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We used two novel commercially available fully automated
sandwich immunoassays for the measurement of MR-proANP
(B.R.A.H.M.S MR-proANP KRYPTOR) and MR-proADM
(B.R.A.H.M.S MR-proADM KRYPTOR) according to the
manufacturer’s instruction manuals (B.R.A.H.M.S GmbH, Hen-
nigsdorf Germany). The design of these assays is based on
immunoluminometric assays described previously [20,21]. Both
parameters were measured in plasma collected at the time
immediately before the initiation of the first dialysis therapy and
kept frozen at 280uC until measurement in a single batch. Other
laboratory parameters reported here were measured from the
same blood collection immediately before the first dialysis therapy.
As described earlier, the limit of quantitation was 4.5 pmol/L
for the MR-proANP assay with a within-run imprecision
coefficient of variation (CV) of ,4.5% between 10 and
20 pmol/L and ,2.5% between 20 and 1000 pmol/L, and
between-run imprecision CV of ,6.5% between 10 and
1000 pmol/L [21]. The limit of quantification was 0.23 nmol/L
for the MR-proADM assay with a within-run imprecision CV of
,4% between 0.5 and 2 nmol/L and ,2% between 2 and
6 nmol/L, and a between-run imprecision CV of ,11% between
0.5 and 2 nmol/L and ,10% between 2 and 6 nmol/L [20]. All
blood samples were processed by personnel blinded from any
patient data.
Study Outcomes
The first outcome of interest was all-cause mortality and
cardiovascular mortality. We also investigated other endpoints
such as cardiovascular disease and peripheral arterial disease.
Cardiovascular mortality was defined as death of myocardial
infarction, heart failure, sudden death, ischemic or hemorrhagic
stroke. Cardiovascular disease (CVD) events were defined as fatal
and non-fatal myocardial infarction, percutaneous transluminal
coronary angioplasty (PTCA), aortocoronary bypass (ACBP),
angiographically-proven coronary stenosis $50%, ischemic cere-
bral infarction or transient ischemic attack. For peripheral arterial
disease (PAD) at least one of the following events was existent:
significant ultrasound- or angiographically-proven vascular steno-
sis, percutaneous transluminal angioplasty (PTA), peripheral
bypass or amputation. An incident PAD event was only considered
as a first time manifestation or a deterioration of PAD in terms of
e.g. a change in PAD stage according to Fontaine. Two patients
were lost to follow-up, one regained renal function and the other
one moved away.
Statistical Methods
At baseline, categorical data were compared using x
2-test and
continuous variables were analyzed using an unpaired t-test or the
non-parametric Wilcoxon rank-sum test. Data are presented as
mean6SD and as median and 25
th and 75
th percentiles for skewed
variables where appropriate.
To investigate the influence of MR-proANP and MR-proADM
on all-cause mortality, cardiovascular mortality, cardiovascular
disease and peripheral arterial disease, multivariable adjusted
Cox-proportional hazards regression models were performed. In
all analyses a p-value of 0.05 was considered significant. Variables
were chosen for the multiple Cox regression analysis since they
were either well-known risk factors for all-cause or CV mortality
or they showed correlations with MR-proADM or MR-proANP.
The first model was adjusted for age, sex, previous cardiovascular
events, diabetes mellitus and type of renal replacement therapy,
which was modeled time-dependently (Model 1). The second
model (Model 2) was additionally adjusted for albumin, C-
reactive protein, current smoking status, native fistula and
echocardiographic data (ejection fraction #60% versus .60%).
Due to sparseness of the data and risk of overfitting, this fully-
adjusted model should only be considered as a sensitivity analysis
to Model 1, which is taken as the main model in this
investigation. Linear relationship assumption of MR-proANP
and MR-proADM in the Cox models was tested, as well as the
proportional hazards assumption. One standard deviation (SD)
was taken as the unit of measure for each of the continuous
outcome variables to ensure comparability of Hazard Ratios. For
ease of interpretation, additional fully adjusted Cox-proportional
hazards regression models were calculated by dividing MR-
proANP and MR-proADM into tertiles and also by stratifying
patients in groups of high risk (both MR-proANP and MR-
proADM in the upper tertile), intermediate risk (only one of the
two parameters in the upper tertile) and low risk (none of the two
parameters in the upper tertile). Adjusted survival curves are
given for each of these risk groups and for each of the tertiles,
holding all covariates fixed at their mean level. We also
performed a sensitivity analysis with censoring at the time of
transplantation. All analyses were conducted in SPSS version
16.0 software (SPSS Inc., Chicago, IL, USA) and R using the
package ‘‘survival’’.
Results
Table 1 provides an overview on the demographic and
laboratory parameters of our study cohort including MR-proANP,
and MR-proADM plasma concentrations. Causes of CKD were
Table 2. Correlations between mid-regional pro-atrial
natriuretic peptide (MR-proANP) and mid-regional pro-
adrenomedullin (MR-proADM) and different parameters.
Correlation coefficient (r)
MR-proANP MR-proADM
Sex (male/female) 20.032 20.042
Age (years) 0.368
c 0.298
c
Diabetes mellitus (no/yes) 0.227
b 0.091
Current smokers (no/yes) 20.084 0.016
Body Mass Index (kg/m
2) 20.090 0.157
a
Left ventricular ejection fraction
(#60%/.60%)
20.262
c 20.257
c
Systolic blood pressure (mmHg) 0.133 0.056
Diastolic blood pressure (mmHg) 20.078 20.082
Laboratory parameters
Albumin (g/dL) 20.198
b 20.223
b
C-reactive protein (mg/dL) 0.003 0.084
Hemoglobin (g/dL) 20.164
a 20.223
b
Creatinine (mg/dL) 20.070 0.032
Comorbidities before dialysis
CAD* 0.168
a 0.082
CVD** 0.150
a 0.075
PAD*** 0.168
a 0.101
For footnotes see Table 1.
ap,0.05;
bp,0.01;
cp,0.001.
doi:10.1371/journal.pone.0017803.t002
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merulonephritis (15%), interstitial and reflux nephropathy (9%),
polycystic kidney disease (9%) and other causes (10%). During the
entire observation period of up to more than 7 years 86 of the
201 patients (43%) passed away, 43% of them due to
cardiovascular events (Figure 1). Patients who did not survive
were older and had more severe illness compared to their event-
free counterparts as indicated by lower serum albumin levels and
impaired left ventricular systolic function, a higher frequency of
diabetes as well as higher prevalence of comorbidities such as
coronary and peripheral artery disease at baseline when
compared to survivors. Almost all patients (99%) had MR-
proANP levels $120 pmol/L, a recently investigated cut point
for diagnosis of acute heart failure in patients with acute dyspnea
[18]. 82% of all patients had at baseline MR-proADM levels
above 1.985 nmol/L which was recently shown as optimal cut
point to predict all-cause mortality in patients with acute dyspnea
[18]. MR-proANP and MR-proADM levels were significantly
higher among the non-survivors compared to the survivors
(9816573 pmol/L vs. 6626439 pmol/L, p,0.001 and
3.2961.17 nmol/L vs. 2.7261.33 nmol/L, p,0.001, respective-
ly). Table 2 lists the correlations between MR-proANP, MR-
proADM and relevant parameters. Both parameters were
moderately correlated with each other (r
2=0.62).
Cox-proportional hazards models for continuous
variables of MR-proANP and MR-proADM
Table 3 presents the results from Cox-proportional hazards
models for MR-proANP and MR-proADM, and all-cause and
cardiovascular mortality as well as CVD and PAD events.
Hazards ratios are adjusted for age, sex, previous CVD events,
diabetes mellitus and time-dependent type of renal replacement
therapy (Model 1) and an extended adjustment additionally for
albumin, CRP, current smoking, native fistula and ejection
fraction (Model 2 as sensitivity analysis). On a continuous scale,
both MR-proANP and MR-proADM were significantly associ-
ated with all-cause and with cardiovascular mortality but not with
the entire group of fatal and non-fatal cardiovascular disease
events. When PAD was used as outcome variable only plasma
MR-proANP but not MR-proADM levels showed a significant
association. These results were only marginally influenced if
further adjusted for albumin, CRP, current smoking, native
fistula and ejection fraction determined by echocardiography
(Model 2).
Table 3. The association of MR-proANP and MR-proADM as well as MR-proANP tertiles and MR-proADM tertiles and furthermore
for patients with high risk (both MR-proANP and MR-proADM in the highest tertile) with different endpoints using multiple Cox-
proportional hazards models.
All-cause
mortality
Cardiovascular
mortality*
Cardiovascular
disease**
Peripheral arterial
disease***
(n events=86) (n events=37) (n events=85) (n events=54)
HR 95%CI p-value HR 95%CI p-value HR 95%CI p-value HR 95%CI p-value
MR-proANP (per 1 SD increase)
a
Model 1 1.44 (1.17, 1.78) 0.001 1.75 (1.28, 2.39) ,0.001 1.15 (0.92, 1.45) 0.221 1.34 (1.02, 1.77) 0.037
Model 2 1.32 (1.04, 1.68) 0.021 1.73 (1.23, 2.44) 0.002 1.06 (0.83, 1.36) 0.642 1.35 (0.99, 1.84) 0.058
MR-proADM (per 1 SD increase)
a
Model 1 1.32 (1.11, 1.58) 0.002 1.41 (1.10, 1.82) 0.007 1.17 (0.98, 1.39) 0.092 1.08 (0.83, 1.41) 0.556
Model 2 1.23 (1.00, 1.50) 0.051 1.43 (1.07, 1.91) 0.015 1.11 (0.90, 1.36) 0.331 1.08 (0.80, 1.46) 0.603
MR-proANP (tertiles)
b
#522 pmol/L 1 1 1 1
523–794 pmol/L 1.07 (0.55, 2.05) 0.847 1.55 (0.50, 4.77) 0.446 0.97 (0.53, 1.78) 0.931 0.90 (0.40, 2.02) 0.802
$795 pmol/L 1.76 (0.93, 3.33) 0.082 2.96 (0.99, 8.89) 0.053 1.07 (0.57, 1.98) 0.839 1.10 (0.49, 2.46) 0.815
MR-proADM (tertiles)
b
#2.40 nmol/L 1 1 1 1
2.41–3.10 nmol/L 1.04 (0.56, 1.92) 0.909 1.09 (0.41, 2.90) 0.862 1.03 (0.59, 1.80) 0.910 1.16 (0.59, 2.27) 0.674
$3.11 nmol/L 2.39 (1.33, 4.28) 0.003 3.16 (1.27, 7.83) 0.013 1.53 (0.88, 2.67) 0.130 1.40 (0.68, 2.85) 0.360
MR-proANP- MR-proADM- Score
b
Low & intermediate risk 1 1 1 1
High risk 2.87 (1.77, 4.65) ,0.001 3.58 (1.73, 7.43) 0.001 1.45 (0.87, 2.44) 0.156 1.59 (0.85, 2.97) 0.147
MR-proANP, mid-regional pro-atrial natriuretic peptide; MR-proADM, mid-regional pro-adrenomedullin.
Model 1: adjusted for age, sex, previous CVD**, diabetes mellitus, time-dependent type of renal replacement therapy.
Model 2: adjusted as in model 1 and additionally for albumin, CRP, current smoking, native fistula, echocardiography (ejection fraction #60% and .60%).
aFor MR-proANP and MR-proADM 1 standard deviation (SD) increment was 524 pmol/L and 1.29 nmol/L, respectively. One SD was taken as the unit of increment for
each of the continuous outcome variables to ensure comparability of Hazard Ratios.
bAdjusted for age, sex, previous CVD**, diabetes mellitus, time-dependent type of renal replacement therapy.
*CV mortality: myocardial infarction, heart failure, sudden cardiac death, ischemic stroke, hemorrhagic stroke.
**CVD: myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, angiographically-proven coronary stenosis $50%, ischemic or
hemorrhagic cerebral infarction, transient ischemic attack, carotid stenosis and carotid endarterectomy.
***PAD: significant ultrasound- or angiographically-proven vascular stenosis, percutaneous transluminal angioplasty, peripheral bypass, amputation.
doi:10.1371/journal.pone.0017803.t003
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mellitus and time-dependent type of renal replacement therapy for mid-regional pro-atrial natriuretic peptide (MR-proANP)
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of MR-proANP and MR-proADM
When we analyzed the data according to tertiles of MR-
proANP and MR-proADM (Table 3), a non-significant trend for
the upper tertile of MR-proANP for all-cause (HR=1.76,
p=0.082) and cardiovascular mortality (HR=2.96, p=0.053)
was observed. However, patients in the upper tertile of MR-
proADM had a significantly increased risk for all-cause
(HR=2.39, p=0.003) as well as cardiovascular mortality
(HR=3.16, p=0.013). Survival curves for all-cause and cardio-
vascular mortality demonstrated that the first and second tertile of
MR-proANP and MR-proADM were similar and only the third
tertile discriminated between survivors and non-survivors
(Figure 2).
This increased risk was clearly identified using a stratification
based on the tertiles of the two peptides by combining the highest
tertiles of MR-proANP ($794 pmol/L) and MR-proADM
($3.11 nmol/L). Table 4 provides the demographic and clinical
characteristics of patients stratified in high risk (both MR-proANP
and MR-proADM in the upper tertile), intermediate risk (only one
of the two parameters in the upper tertile) and low risk (none of the
two parameters in the upper tertile). The increase in risk with
respect to all-cause mortality was almost identical when we
compared the high risk group versus intermediate risk group
(HR=2.70, p=0.001) and the high risk group versus low risk
group (HR=3.02, p,0.001). The risk was only increased when a
patient had both parameters in the upper tertile, although
demographic, clinical and laboratory variables were similar among
the intermediate and high risk group. The high risk group was
associated with an about 3-fold higher risk for all-cause mortality
(HR=2.87, p,0.001) and cardiovascular mortality (HR=3.58,
p=0.001) when compared to the remaining patients (Table 3 and
Figure 2).
Sensitivity analysis
It might introduce some considerable bias to the data analysis
when a patient is selected for transplantation and follow-up time is
censored at the time of transplantation. For this reason the above
main analysis was performed by a time-dependent modeling of the
renal replacement therapy status as discussed earlier [22,23]. To
exclude that this procedure has influenced our main findings, we
performed a sensitivity analysis with classical censoring at the time
of transplantation which did, however, not reveal any substantial
differences in HRs compared to the primary analysis (see Table
S1). Due to sparseness of the data and risk of overfitting we also
calculated a simple model only adjusting for age and sex that did
not show major differences in estimates compared to Model 1. A
further sensitivity analysis was calculated where Model 1 was
additionally adjusted for hemoglobin. No substantial differences in
estimates could be observed.
Discussion
The study at hand investigated the two peptides MR-proANP
and MR-proADM in a prospective long-term cohort study of
incident dialysis patients. We observed that increased concentra-
tions of both peptides are associated with an increased risk of all-
cause as well as cardiovascular mortality and this risk was about
threefold elevated when both parameters were in the upper tertile
of the entire patient group. This elevation of both parameters
discriminated especially patients with intermediate and high risk
which were otherwise similar in terms of clinical and laboratory
parameters. Therefore, the incremental benefit to identify high risk
patients is achieved by the combined evaluation of these two
biomarkers. If a patient had an isolated increase in one of the two
parameters, the risk was similar compared to patients which did
show an increase at all (see Figure 2). Obviously, both peptides
accumulate as a result of a series of pathophysiological parameters
detrimental to survival. Our results indicate that cut points for the
diagnosis of acute heart failure or for the prediction of mortality
established in cohorts of patients not recruited because of end-
stage renal disease (ESRD) do not necessarily apply for ESRD
patients. In the present study MR-proANP and MR-proADM
values above these cut-off points were demonstrated in a very high
proportion of patients which might not only reflect the
hemodynamic disturbances and risk prediction. Both peptides
are produced in the kidney with important biological functions for
the kidney. A compensatory increase in concentrations as well as a
reduced clearance of both peptides requires searching for suitable
cut points in patients with ESRD. Interestingly, we observed in the
present study not only higher cut points of the two peptides but
also a combination of both parameters to be predictive for
outcomes.
Presumably, ANP reflects the central volume overload and
intrinsic heart disease, whereas ADM reflects the decompensated
reaction to the multifactorial stress state in preserving the integrity
of the cardiovascular system in ESRD (22). It is of interest that we
observed a strong association with all-cause and cardiovascular
mortality but not with cardiovascular events combining fatal and
non-fatal events. The slight increase in risk for CVD events
(HR=1.45, 95%CI 0.87–2.44) if both peptides were in the upper
tertile was driven by the fatal CVD events. If these fatal events
were excluded, the estimates for non-fatal CVD events did not
show in any direction (HR=1.04, 95%CI 0.45–2.39). This
underscores that the pronounced increases of both peptides might
reflect more the hemodynamic disturbances related to cardiac
dysfunction rather than atherosclerotic processes resulting in non-
fatal CVD events without hemodynamic decompensation. The
combined measurement of these two peptides might provide
surrogate variables for volume status but also act as an early
indicator of deteriorating hemodynamic changes.
The diagnostic and prognostic utility of MR-proADM has been
shown in various non-CKD cohorts and for different endpoints
such as heart failure, cardiovascular events, and all-cause mortality
[15–18]. In hemodialysis patients plasma ADM levels were
associated with clinical conditions such as cardiac dysfunction,
excessive blood volume and systemic inflammation but also with
cardiovascular outcomes and mortality [13,24]. There is strong
evidence that MR-proADM is produced in the kidney to exert
hemodynamic actions on renal function [4]. That might be an
explanation why MR-proADM was one of the strongest predictors
for the progression of early stages of kidney impairment, which
was even independent from baseline GFR measured by iohexol
clearance [6,7].
It is currently unclear whether the systemic and renal haemo-
dynamic effects are caused by MR-proADM itself or predomi-
tertiles (top), mid-regional pro-adrenomedullin (MR-proADM) tertiles (middle) and patients stratified for high risk (both MR-
proANP and MR-proADM in the upper tertile), intermediate risk (only one of the two parameters in the upper tertile) and low risk
(none of the two parameters in the upper tertile) (bottom). Tertiles for MR-proANP were #522, 523–794, and $795 pmol/L, respectively.
Tertiles for MR-proADM were #2.40, 2.41–3.10, and $3.11 nmol/L, respectively.
doi:10.1371/journal.pone.0017803.g002
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Low risk
(n=107)
Intermediate risk
(n=51)
High risk
(n=43)
Sex (male/female), n (%) 69/38 (64/36%) 32/19 (63/37%) 23/20 (53/47%)
Age (years) 57615 67611 66611
Diabetes mellitus, n (%) 34 (32%) 22 (43%) 19 (44%)
Current smokers, n (%) 26 (24%) 9 (18%) 9 (21%)
Body Mass Index (kg/m
2) 26.064.1 26.664.4 25.565.4
Start of dialysis with
Hemodialysis, n (%) 81 (76%) 49 (96%) 39 (91%)
Central venous catheter, n (%) 9 (11%) 9 (18%) 7 (18%)
Native fistula, n (%) 58 (72%) 32 (65%) 24 (62%)
Graft, n (%) 14 (17%) 8 (16%) 8 (21%)
Peritoneal dialysis, n (%) 26 (24%) 2 (4%) 4 (9%)
Year of start of dialysis
2000–2003, n (%) 55 (51%) 26 (51%) 17 (40%)
2004–2006, n (%) 52 (49%) 25 (49%) 26 (60%)
Echocardiography
Missing, n (%) 5 (5%) 4 (8%) 6 (14%)
Ejection fraction #60%, n (%) 36 (34%) 27 (53%) 23 (53%)
Ejection fraction .60%, n (%) 66 (62%) 20 (39%) 14 (33%)
Systolic blood pressure (mmHg) 151622 154621 157625
Diastolic blood pressure (mmHg) 84612 81611 82615
Laboratory parameters
MR-proANP (pmol/L) 4886188
[322; 512; 625]
9056521
[546; 788; 1055]
14436455
[975; 1422; 1811]
MR-proADM (nmol/L) 2.1960.55
[1.84; 2.31; 2.57]
3.2860.78
[2.71; 3.15; 3.69]
4.5161.54
[3.46; 4.15; 4.93]
Albumin (g/dL) 3.860.6 3.760.6 3.560.7
C-reactive protein (mg/dL) 2.664.5
[0.3; 0.8; 2.1]
4.367.4
[0.3; 0.9; 4.4]
2.964.3
[0.4; 1.6; 3.1]
Calcium (mmol/L) 2.1860.28 2.0860.28 2.0560.24
Phosphorus (mmol/L) 2.0260.62
[1.59; 1.95; 2.40]
1.9060.54
[1.54; 1.90; 2.14]
2.0460.66
[1.57; 1.97; 2.39]
Hemoglobin (g/dL) 11.561.7 11.161.6 10.561.8
Creatinine (mg/dL) 7.362.7
[5.5; 6.8; 8.7]
7.462.5
[5.8; 7.1; 8.1]
7.262.9
[5.3; 6.4; 8.5]
HbA1c (% Hb) 6.5161.44 6.5762.02 6.1661.21
Total cholesterol (mg/dL) 192654 192652 173644
LDL cholesterol (mg/dL) 122646 120643 107638
HDL cholesterol (mg/dL) 46.2614.2 44.8613.0 49.2611.1
Triglycerides (mg/dL) 170690
[111; 143; 212]
1786136
[109; 139; 194]
142676
[100; 121; 161]
Comorbidities before dialysis
CAD*, n (%) 15 (14%) 12 (23.5%) 9 (20.9%)
CVD**, n (%) 28 (26%) 19 (37.3%) 14 (32.6%)
PAD***, n (%) 18 (17%) 5 (9.8%) 12 (27.9%)
Follow-up
Follow-up time (months){ 63.2626.6 56.3628.5 36.1625.3
All-cause mortality, n (%) 32 (30%) 26 (51%) 28 (65%)
Transplantation, n (%) 44 (41%) 8 (15.7%) 7 (16.3%)
For footnotes see Table 1.
doi:10.1371/journal.pone.0017803.t004
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MR-proADM is currently unclear. However, the eligible mea-
surement of the active hormone ADM was doubted largely mainly
due to the short half-life of 22 minutes and the partial binding to
complement factor H [25–27]. Since MR-proADM and ADM are
stoichiometrically generated and MR-proADM is more stable
[28], MR-proADM seems to be at least a reliable surrogate
marker for the active hormone ADM. The same holds true for
MR-proANP and ANP. A perfect correlation between the
midregional parts of the prohormones and the respective active
hormones can not be expected since differences in the metabolic
rates are assumed. Nevertheless, the midregional parts of the
prohormones seem to mirror the hard to measure active
hormones, otherwise the manifold associations with clinical
endpoints would not be observed.
Our findings complement and extend previously reported
cohort studies of end-stage renal disease for the biomarkers ANP
[8–12] and ADM [13] (Table 5). Most of these studies were done
in small cohorts and/or short observation periods and only one
study considered ADM. Our cohort differs from these earlier
studies since we investigated baseline levels in patients before first
dialysis treatment. It therefore avoids a potential survival bias
caused by the higher mortality rates during the first year of
dialysis treatment which are not considered in cross-sectional
cohorts or mixed cohorts of prevalent and incident dialysis
patients.
MR-proANP concentrations were substantially increased in our
cohort of dialysis patients when compared to patients with mild to
moderate impairment of kidney function [6] as well as to a high
risk cohort of heart failure patients [14]. While the role of ANP as
regulator of the cardiovascular system is established, its physio-
logical regulatory role on transport processes in the nephron is
under debate [5]. ANP has been known to be primarily produced
in the cardiac atrium, however, up-regulation of ANP mRNA
expression has been demonstrated in extra-atrial tissues such as the
kidneys [29]. The exact pathophysiological significance of kidney-
synthesized ANP has not been defined yet.
To date prognostic biomarkers which predict outcome in this
high risk cohort of CKD patients are sparse but highly demanded.
However, as we discussed recently [6] the measurement of the
active hormones has little clinical utility due to the short half life of
most of the bioactive peptides, their immediate binding to
receptors [27], their interaction with binding proteins [30] and
several technical difficulties [30]. This is even more important
when long-term stored samples are analysed because the active
hormones undergo degradation even in frozen samples which is
not the case for their propeptides. Therefore, replacing the
problematic measurement of bioactive rapidly cleared peptides by
measuring the non-functional, stable peptides MR-proANP and
MR-proADM derived from their precursors represents a valuable
advance for clinical practice. Interestingly, proteolytic degradation
of pro-ANP seems to be mainly directed to the N- and C-terminal
Table 5. Prospective studies in dialysis patients investigating the association between atrial natriuretic peptide (ANP) and
adrenomedullin (ADM) on clinical outcomes.
Study Design Follow-up
Endpoint and number
of patients with
endpoint HR (95% CI)
Atrial natriuretic peptide (ANP)
Zoccali et al.
2001 [11]
Cohort study: 246
patients with end-stage
renal disease without
heart failure
26 mos. All-cause mortality: 63
CV mortality: 35
All-cause mortality: 2.39 (1.59–3.59) for ln ANP adjusted
for Kt/V, age, ln albumin, ln cholesterol, diabetes.
4.22 (1.79–9.92) for patients in the 3
rd vs. the 1
st tertile of ANP.
CV mortality: 2.13 (1.29–3.52) for ln ANP adjusted for calcium, Kt/V, age.
3.80 (1.44–10.03) for patients in the 3
rd vs. the 1
st tertile of ANP.
Goto et al.
2002 [12]
Cohort study: 53
hemodialysis patients
11.3 mos. Cardiac events: 13 118621 vs. 5665 pg/mL in patients with
compared to without cardiac events.
Nakatani et al.
2003 [8]
Cohort study: 105
hemodialysis patients
24 mos. Cardiac death: 11 32 (4–252) for ANP.50 pg/mL vs. ,50 pg/mL.
3.5 (1.6–7.4) for ln ANP (adjusted for LVMI and CRP).
Odar-Cederlo ¨f
et al.
2003 [9]
Cohort study: 33
hemodialysis patients
47 mos. All-cause mortality: 18
Early deaths
(,1 year): 6
All-cause mortality: ANP (predialysis) 1.004 (1.000–1.007);
ANP (postdialysis): 1.006 (1.000–1.012).
Early deaths: ANP (predialysis) 1.007 (1.001–1.013);
ANP (postdialysis) 1.006 (0.995–1.016).
Yoshihara et al.
2005 [13]
Cohort study: 67
hemodialysis patients
1 yr. 7 patients died
and 8 CV events
Mortality and CV events combined: 1.41 (0.36–5.56)
for ANP$230 (median) compared to ANP,230.
Rutten et al.
2006 [10]
Cohort study: 68 peritoneal
dialysis patients
1.5–4.5 yrs. All-cause
mortality: 10
11.3 (1.4–91.9) for ANP.median compared to ANP,median.
7.9 (0.9–72.1) adjusted for age, comorbidity, residual GFR.
This study Incident cohort study:
201 dialysis patients
56 mos. All-cause mortality: 86
CV mortality: 37
All-cause mortality: 1.44 (1.17–1.78) per SD increase of ANP.
CV mortality: 1.75 (1.28–2.39) per SD increase of ANP.
Adrenomedullin (ADM)
Yoshihara et al.
2005 [13]
Cohort study: 67
hemodialysis patients
1 yr. 7 patients died
and 8 CV events
Mortality and CV events combined: 4.55 (1.23–16.80)
for ADM$4.55 (median) compared to ADM,4.55.
This study Incident cohort study:
201 dialysis patients
56 mos. All-cause mortality: 86
CV mortality: 37
All-cause mortality: 1.32 (1.11–1.58) per SD increase of ADM.
CV mortality:1.41 (1.10–1.82) per SD increase of ADM.
Combination of the upper tertiles of ANP and ADM compared to other tertiles
This study Incident cohort study:
201 dialysis patients
56 mos. All-cause mortality: 86
CV mortality: 37
All-cause mortality: 2.82 (1.76–4.53) per SD increase of ANP.
CV mortality: 3.30 (1.62–6.70) per SD increase of ANP.
CV, cardiovascular; SD, standard deviation.
doi:10.1371/journal.pone.0017803.t005
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promoting this region to a suitable target of measurement. In
addition, circulating mid-regional fragments are not influenced by
a binding protein, making it suitable for immunometric analysis.
Strengths and limitations of the study
The prospective recruitment of all patients starting dialysis
treatment over a period of six years in a clearly described area
allowed a complete recruitment of patients requiring renal
replacement therapy with almost no loss to follow-up during a
long observation period. We can therefore exclude the most
important bias of cross-sectional studies with a mix of prevalent
and incident cases and the resulting survival bias. We furthermore
considered even the observation period following kidney trans-
plantation by modeling the treatment status in a time-dependent
model, but on the other hand excluded by sensitivity analysis, that
this procedure has obscured our results.
There are also some limitations of this study. A first limitation is
the relatively small number of patients and events. We therefore
could only adjust our analyses for a small number of variables (6
variables in Model 1). An extended adjustment with more
variables (Model 2 and additional sensitivity analyses) was
provided but should only be considered as sensitivity analysis.
Interestingly, the estimates for MR-proADM and MR-proANP
remained widely stable in Models 1 and 2, the additional
sensitivity analyses and a very simple model only adjusted for
age and sex. This argues for a pronounced independence of the
two investigated variables for the prediction of endpoints. Second,
we examined patients at the time immediately before renal
replacement therapy was started. Therefore, some patients might
not have been in a steady metabolic or extracellular volume state
of the parameters evaluated. Concentrations of these hormones
might therefore not necessarily be applicable to other cohorts of
patients with CKD. On the other hand, values measured after the
start of dialysis treatment as done in other mostly smaller studies
might represent dialysis dose or dialysis efficacy and thus answer a
different question. Third, our study includes only Caucasian
patients of a clearly described geographical region with almost
complete ascertainment of incident dialysis patients over a defined
period of time. It therefore lacks generalizability to other ethnic
populations as well as other recruitment procedures. Finally, since
the measurements of the two peptides are not rigorously
standardized, concentrations measured by various assays are not
necessarily comparable.
Conclusion
Among incident dialysis patients MR-proANP and MR-
proADM were shown to be associated with all-cause mortality
and cardiovascular mortality, with the highest risk when both
parameters were in the upper tertiles.
Supporting Information
Table S1 The association of MR-proANP and MR-proADM as
well as MR-proANP tertiles and MR-proADM tertiles and
furthermore for patients with high risk (both MR-proANP and
MR-proADM in the highest tertile) with different endpoints using
multiple Cox-proportional hazards models.
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